Albuferon
Navigation Links
Albuferon in Medical News
HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatit...HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C
ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype...New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...Drugs in Select Countries (includes corresponding Graph/Chart) II-3 albuferon - Rising Above the Standards II-4 Viramidine - Next-Generation Ribaviri...s with GI-5005 II-57 Human Genome Gets Encouraging Interim Results with albuferon II-58 Intarcia Releases Study Results of Omega Interferon II-58 Nau...Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
... of required injections. As a result, the value of HGSI shares was reduced by 57% the day the study data was released. I can't help but wonder how albuferon might have performed in combination with our Hemopurifier(R)? Regardless, a drug candidate wishing to supplant SOC therapy in the market will need to...Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE HARBOR STATEMENT This announcement contains forward-looking statements within ...Albuferon in Medical Technology
Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
- Albuferon 900-mcg dosed every two weeks achieved an SVR rate at least comparable to Pegasys dosed every week (ITT analysis), with more favorable quality-of-life scores - ROCKVILLE, Md., June 07, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the top-line final results......lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the submission of global marketing applications is expected in fall 2009. BENLYSTA successfully met its pr...
Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE ......as many injections, in two pivotal Phase 3 trials, albuferon (albinterferon alfa-2b) met the primary efficacy e...eron alfa-2a) - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve... the half-life of the therapeutic proteins. albuferon is being developed by HGS and Novartis for the tre...
... - 900-mcg albuferon (albinterferon alfa-2b) dosed every two weeks met ...c hepatitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve...Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...
...e reported our company's first Phase 3 results for albuferon in chronic hepatitis C, and the data were positive. We will have results of the second albuferon Phase 3 trial in March 2009, and the results of ou...or 2008 included $35.4 million recognized from the albuferon agreement with Novartis, and $6.5 million in reven...
...an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/ . HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking st...
... that the results of ACHIEVE 2/3 demonstrated that albuferon (albinterferon alfa-2b) met its primary endpoint o...ic response was comparable for the 900-mcg dose of albuferon administered every two weeks, vs. the standard 180...e. The results of ACHIEVE 1, the Phase 3 trial of albuferon in genotype 1 chronic hepatitis C, are expected in...
...ted from spam bots, you need JavaScript enabled to view it or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...Albuferon in Biological Technology
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has successfully completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. BENLYSTA has successfully m......lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...
...cted by Novartis evaluating safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...on a weekly basis. A monthly dosing schedule with albuferon may well result in more patients choosing to be tr...
...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
... - Positive results for second Phase 3 trial of albuferon (R) in chronic hepatitis C; global marketing ap...ved our first product sales with ABthrax, and both albuferon and LymphoStat-B(R) continued to make excellent pr...e results from the second of two pivotal trials of albuferon in chronic hepatitis C, and we plan global marketi......erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. HGS ...
...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon successfully met its primary endpoint in the first of two Phase 3 trials in chronic hepatitis C; results of the second albuferon Phase 3 trial are expected in March 2009. Two Phase 3 clinical trials of L...
...ted by Novartis to evaluate safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...ctions." In December 2008, HGS announced that albuferon met its primary endpoint of non-inferiority to peg...
... - albuferon (albinterferon alfa-2b) met its primary endpoint o...patitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious adverse events, se...gasys) in ACHIEVE 2/3, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...
Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
... are on track to report our first Phase 3 data for albuferon in December 2008. We are on track to report our fi...emains on track to have the first Phase 3 data for albuferon - from the ACHIEVE 2/3 trial - in December 2008. A...nsion 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sc...Other TagsCigarCigarBaskBaskOther Contentsclostridiumclostridiumcircumcisioncircumcisioncircumcisioncloudycloudycloudyclassicclassicclassicclassicclassicclassicclavicleclaw
salvoMSFHarmonicaEndarterectomySpecifyEdentulousnesshandednessFraternityDilatorsCigarloosingBaskPhoneticsQuackery
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leadin... today announced the expansion of its services to ... Dr. Doug Macmillan. , ... pleased to announce that Dr. Doug Macmillan, an e... an additional advanced training seminar. RTDenta...
(Date:11/25/2009)....,Nov.25/PRNewswire/--TheBartleHallConventionCente...niconDec.9-10,whenKansasCityhoststhelatestinaserie...isfreecliniceventhasthepotentialtobethebiggestoney...ndbeheldonweekdaysinsteadofoveraweekend,"SheriWood...ndpresidentoftheNationalAssociationofFreeClinics(N...
(Date:11/25/2009)...if.,Nov.25/PRNewswire/--Thanksgivingmealswillbedel...aterLongBeachareathankstoFaithInAction/VolunteerAc...IAH),adivisionofSCANHealthPlan.Formorethan17yearst...odeliverwarmThanksgivingmealstoseniorsinneedinLong...andsurroundingcities. ,, "Ourwarmholidaymealsar...
(Date:11/25/2009)...alEndorsements,Business,andPressJoinEfforttoEducat...e/--Onceagain,theNationalBipolarFoundationandtheMe...ir"Safe,tilStable"program,whichisnowbeingwidelyacc...der.Today,theNationalBipolarFoundationreceivedapro...lfromtheLt.GovernorofLouisianaMitchLandrieu.TheNat...
(Date:11/25/2009)...e blood pressure? This simple question has been t...Stress-related gene Modulates High Blood Pressure ...e? This simple question has been the focus of int...s for the first time established a link between a ...onse to stress in mice as well as humans. The stud...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental [1] Kansas City Prepares for Largest Free Health Clinic[0] SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors[0] First Time-Door is Open for Family Discussion of Bipolar Disorder[1] New stress-related gene modulates high blood pressure in mice and men
(Date:11/24/2009)... opening new doors to understanding how sounds ass...f a marine mammal or if they hear it at all. , ...ners that NASA uses to detect flaws in the space s...ng scientists to peek inside the giant head of a w...sional replicas of a whale,s hearing anatomy using...
(Date:11/24/2009)...weakened and flabby arteries from collapsing have ... stents are no longer needed -- once the arteries ...sly, doctors had no choice but to leave them in pl...sity,s Department of Biomedical Engineering has de...arries drugs where they,re needed, then dissolves....
(Date:11/24/2009)...American College of Medical Toxicology (ACMT) have...tion of the Journal of Medical Toxicology (JMT),...rch 2010. It was previously published by the Univ... Medical Toxicology , an international, peer-revie... and practice of medical toxicology. The quarterl...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2International Products Corp s Lab Offers Filter Membrane Compatibility and Studies 12770 1International Products Corp s Lab Offers Filter Membrane Compatibility and Studies 12770 2Researcher finds Girl Scout meetings provide an opportunity to increase girls physical activity 8990 1Researcher finds Girl Scout meetings provide an opportunity to increase girls physical activity 8990 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 1Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 8985 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |